Immunogenic targets in non-small cell lung cancer: More is more

Clinical Cancer Research

Volumn 11, Issue 15, 2005, Pages 5331-5332

  Gnjatic, Sacha ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; XAGE 1B ANTIGEN;

ANTIBODY RESPONSE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOGENESIS; DENDRITIC CELL; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GERM CELL; HUMAN; IMMUNOGENICITY; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL DESTRUCTION; TUMOR CELL CULTURE; TUMOR GROWTH; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; GENE LIBRARY; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PROGNOSIS;

EID: 23044472987     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0880     Document Type: Editorial

References (24)

1. Palmer M, Parker J, Modi S, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001;3:49-57.
2. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001;98:8809-14.
3. Gnjatic S, Jäger E, Chen W, et al. CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci U S A 2002;99:11813-8.
4. Salazar LG, Fikes J, Southwood S, et al. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003;9:5559-65.
5. Salgia R, LynchT, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003;21:624-30.
6. Atanackovic D, Altorki NK, Stockert E, et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004;172:3289-96.
7. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004;22:2808-15.
8. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene) -specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004;101:13885-90.
9. Raez LE, Cassileth PA, Schlesselman JJ, et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:2800-7.
10. Morse MA, Garst J, Osada T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005;3:9.
11. Chang GC, Lan HC, Juang SH, et al. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer 2005;103:763-71.
12. van der Bruggen P, Traverseri C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-50.
13. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
14. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1.
15. Ross MT, Grafham DV, Coffey AJ, et al. The DNA sequence of the human X chromosome. Nature 2005;434:325-37.
16. Scanlan MJ, Altorki NK, Gure AO, et al. Expression of cancer-testis antigens in lung cancer: definition of bromodomain teslis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett 2000;150:155-64.
17. Gnjatic S, Atanackovic D, Jager E, et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A 2003;100:8862-7.
18. Wang T, Fan L, Watanabe Y, et al. L552S, an alternatively spliced isoform of XAGE-1, is overexpressed in lung adenocarcinoma. Oncogene 2001;20:7699-709.
19. Zendman AJ, van Kraats AA, den Hollander AI. Weidle UH, Ruiter DJ, van Muijen GN. Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis. Int J Cancer 2002;97:195-204.
20. Egland KA, Kumar V, Duray P, Pastan I. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol CancerTher 2002;1:441-50.
21. Ali Eldib AM, Ono T, Shimono M, et al. Immunoscreening of a cDNA library from a lung cancer cell line using autologous patient serum: Identification of XAGE-1b as a dominant antigen and its immunogenicity in lung adenocarcinoma. Int J Cancer 2004;108:558-63.
22. Sugita M, Geraci M, Gao B, et al. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 2002;62:3971-9.
23. Hodi FS, Schmollinger JC, Soiffer RJ, et al. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci USA 2002;99:6919-24.
24. Woo EY, Yeh H, Chu CS, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6.